Obexelimab Reduced Glucocorticoid-Associated Toxicity in Patients With IgG4-Related Disease: Results From the Phase 3 Randomized, Placebo-Controlled Indigo Trial

obexelimab (ZB012) - Zenas BioPharma

https://eppro02.ativ.me/web/page.php?page=session&project=ACR26&id=3564332

Matthew Baker1; Cory Perugino2; Emanuel Della-Torre3; Wen Zhang4; Emma L. Culver5; Yoshiya Tanaka6; Vinciane Rebours7; Mollie Carruthers8; Audrey Wells9; Thomas Greene10; Allen Poma9; John Stone11

Sep 8, 2026